Resecting Residual Gastrointestinal Stromal Tumors Improved Survival

SAN FRANCISCO (IMNG) - Surgically removing residual gastrointestinal stromal tumors in patients who respond to imatinib therapy significantly increased time to tumor progression to 88 months, compared...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news